Clinical Trial Update: Lonafarnib Boosted With Ritonavir With and Without Peginterferon Alfa-2a (PEG IFN-a) in HDV (LOWR-2) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating lonafarnib with and without ritonavir, with and without peginterferon alfa-2a, in chronic hepatitis D infection has completed with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis D

Drugs mentioned

• Lonafarnib (lonafarnib)
• Peginterferon alfa-2a (peginterferon alfa-2a)
• Ritonavir (Ritonavir)

Snippet

Sponsor: Eiger BioPharmaceuticals | Conditions: Chronic Hepatitis D Infection | Phase 2 | Status: COMPLETED | Results posted: 2023-02-21